Investigation Report on China Sodium Ibandronate Market, 2010-2019
Description
Bone metastasis is common in patients with advanced malignant tumor. According to the statistics, each year millions of tumor patients especially patients with breast cancer, prostate cancer and lung cancer suffer from bone metastasis around the world. Bone metastasis of malignant tumor often result in severe lesions in bone including such skeletal-related events as bone pain, pathological fracture, spinal cord compression and hypercalcemia. Once Bone metastasis occurs, most patients will suffer from different degrees of pain even pathological fracture, which will obviously influence their life quality.
The most common drug for bone metastasis is diphosphonate. Three generations of diphosphonate, respectively, etidronate and clodronate representated by Bonefos, pamidronate and alendronate sodium represented by Bonin as well as sodium ibandronate and zoledronic acid are now used in the clinic.
First registered and used in the clinic under the trade name of Bondronat in Germany and Austria in 1996, sodium ibandronate was approved by FDA to come into the market as a daily treatment of osteoporosis under the trade name of Boniva. However, since drug makers later developed more convenient dose, Boniva has not appeared in the American market until FDA approved its monthly use in 2005.
The number of new cases of cancer is over 3 million each year in China, among which about 50% suffer from bone metastasis. In 2001, some local enterprises began to apply for relevant products of sodium ibandronate and succeeded in 2002. In Jul. 2006, sodium ibandronate produced by Roche entered China under the trade name of Bondronat. Since then, sodium ibandronate has developed fast, annual sales value rising from CNY 50.38 million in 2010 to CNY 87.23 million in 2014 and CAGR during this period reaching up to 14.71%. sodium ibandronate enjoys a vast demand in China. Currently, sodium ibandronate market in China is mainly occupied by the following companies: Science & Technology General Company Hebei Medical University, Roche Diagnostics GmbH GE), Hencer Pharmacy and Easton Pharmaceutical Co., Ltd, among which Science & Technology General Company Hebei Medical University has the largest market share of about 58% for sales value in 2014.
With the degradation of environmental pollution and the ageing population, the number of new cases of cancer each year is expected to keep increasing, which shall boost the growth of sodium ibandronate market in China.
Readers can get at least the following information from this report:
Bone metastasis is common in patients with advanced malignant tumor. According to the statistics, each year millions of tumor patients especially patients with breast cancer, prostate cancer and lung cancer suffer from bone metastasis around the world. Bone metastasis of malignant tumor often result in severe lesions in bone including such skeletal-related events as bone pain, pathological fracture, spinal cord compression and hypercalcemia. Once Bone metastasis occurs, most patients will suffer from different degrees of pain even pathological fracture, which will obviously influence their life quality.
The most common drug for bone metastasis is diphosphonate. Three generations of diphosphonate, respectively, etidronate and clodronate representated by Bonefos, pamidronate and alendronate sodium represented by Bonin as well as sodium ibandronate and zoledronic acid are now used in the clinic.
First registered and used in the clinic under the trade name of Bondronat in Germany and Austria in 1996, sodium ibandronate was approved by FDA to come into the market as a daily treatment of osteoporosis under the trade name of Boniva. However, since drug makers later developed more convenient dose, Boniva has not appeared in the American market until FDA approved its monthly use in 2005.
The number of new cases of cancer is over 3 million each year in China, among which about 50% suffer from bone metastasis. In 2001, some local enterprises began to apply for relevant products of sodium ibandronate and succeeded in 2002. In Jul. 2006, sodium ibandronate produced by Roche entered China under the trade name of Bondronat. Since then, sodium ibandronate has developed fast, annual sales value rising from CNY 50.38 million in 2010 to CNY 87.23 million in 2014 and CAGR during this period reaching up to 14.71%. sodium ibandronate enjoys a vast demand in China. Currently, sodium ibandronate market in China is mainly occupied by the following companies: Science & Technology General Company Hebei Medical University, Roche Diagnostics GmbH GE), Hencer Pharmacy and Easton Pharmaceutical Co., Ltd, among which Science & Technology General Company Hebei Medical University has the largest market share of about 58% for sales value in 2014.
With the degradation of environmental pollution and the ageing population, the number of new cases of cancer each year is expected to keep increasing, which shall boost the growth of sodium ibandronate market in China.
Readers can get at least the following information from this report:
- market size of sodium ibandronate in China
- competitive landscape of sodium ibandronate in Chinese market
- price of sodium ibandronate made by different enterprises in China
- market outlook of sodium ibandronate in China
- manufacturers of anti-tumor drugs
- investors/ research institutions interested in Chinese medicine market
- any interest in the Chinese medicine market, please contact CRI for customized survey service
1 RELATED CONCEPTS OF SODIUM IBANDRONATE
1.1 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF SODIUM IBANDRONATE IN CHINA
2.1 Patent and Approval Status of Sodium Ibandronate in China
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON SALES STATUS OF SODIUM IBANDRONATE IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR MANUFACTURERS OF SODIUM IBANDRONATE IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF SODIUM IBANDRONATE IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF SODIUM IBANDRONATE IN CHINESE HOSPITALS IN 2014
6.1 Roche Diagnostics GmbH GE (Trade Name: BONVIVA)
6.2 Hencer Pharmacy (Trade Name: Jia Nuo Shun)
6.3 Easton Pharmaceutical Co., Ltd
6.4 Science & Technology General Company Hebei Medical University (Trade Name: Aiben)
7 MAJOR MANUFACTURERS OF SODIUM IBANDRONATE IN CHINESE MARKET, 2010-2014
7.1 Hencer Pharmacy
7.2 Science & Technology General Company Hebei Medical University
7.3 Roche Diagnostics GmbH
7.4 Easton Pharmaceutical Co., Ltd
8 MARKET OUTLOOK OF SODIUM IBANDRONATE IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
TABLE OF SELECTED CHARTS
Chart Approval Information of Sodium Ibandronate in China
Chart Sales Status of Sodium Ibandronate in China
Chart Sales Value of Sodium Ibandronate in China, 2010-2014
Chart Sales Value of Sodium Ibandronate in Some Regions in China, 2010-2014
Chart Sales Volume of Sodium Ibandronate in China, 2010-2014
Chart Market Share of TOP4 Manufacturers of Sodium Ibandronate for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Sodium Ibandronate Made by Science & Technology General Company Hebei Medical University in China, 2010-2014
Chart Sales Value and Market Share of Sodium Ibandronate Made by Hencer Pharmacy in China, 2010-2014
Chart Sales Value and Market Share of Sodium Ibandronate Made by Roche Diagnostics(GE) in China, 2010-2014
Chart Sales Value and Market Share of Sodium Ibandronate Made by Easton in China, 2010-2014
Chart Price of Sodium Ibandronate Made by Roche Diagnostics GmbH GE in Some Chinese Cities in 2014
Chart Price of Sodium Ibandronate Made by Hencer Pharmacy in Some Chinese Cities in 2014
Chart Price of Sodium Ibandronate Made by Easton Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Sodium Ibandronate Made by Science & Technology General Company Hebei Medical University in Some Chinese Cities in 2014
1.1 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF SODIUM IBANDRONATE IN CHINA
2.1 Patent and Approval Status of Sodium Ibandronate in China
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON SALES STATUS OF SODIUM IBANDRONATE IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR MANUFACTURERS OF SODIUM IBANDRONATE IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF SODIUM IBANDRONATE IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF SODIUM IBANDRONATE IN CHINESE HOSPITALS IN 2014
6.1 Roche Diagnostics GmbH GE (Trade Name: BONVIVA)
6.2 Hencer Pharmacy (Trade Name: Jia Nuo Shun)
6.3 Easton Pharmaceutical Co., Ltd
6.4 Science & Technology General Company Hebei Medical University (Trade Name: Aiben)
7 MAJOR MANUFACTURERS OF SODIUM IBANDRONATE IN CHINESE MARKET, 2010-2014
7.1 Hencer Pharmacy
7.2 Science & Technology General Company Hebei Medical University
7.3 Roche Diagnostics GmbH
7.4 Easton Pharmaceutical Co., Ltd
8 MARKET OUTLOOK OF SODIUM IBANDRONATE IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
TABLE OF SELECTED CHARTS
Chart Approval Information of Sodium Ibandronate in China
Chart Sales Status of Sodium Ibandronate in China
Chart Sales Value of Sodium Ibandronate in China, 2010-2014
Chart Sales Value of Sodium Ibandronate in Some Regions in China, 2010-2014
Chart Sales Volume of Sodium Ibandronate in China, 2010-2014
Chart Market Share of TOP4 Manufacturers of Sodium Ibandronate for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Sodium Ibandronate Made by Science & Technology General Company Hebei Medical University in China, 2010-2014
Chart Sales Value and Market Share of Sodium Ibandronate Made by Hencer Pharmacy in China, 2010-2014
Chart Sales Value and Market Share of Sodium Ibandronate Made by Roche Diagnostics(GE) in China, 2010-2014
Chart Sales Value and Market Share of Sodium Ibandronate Made by Easton in China, 2010-2014
Chart Price of Sodium Ibandronate Made by Roche Diagnostics GmbH GE in Some Chinese Cities in 2014
Chart Price of Sodium Ibandronate Made by Hencer Pharmacy in Some Chinese Cities in 2014
Chart Price of Sodium Ibandronate Made by Easton Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Sodium Ibandronate Made by Science & Technology General Company Hebei Medical University in Some Chinese Cities in 2014
